Clinical Trial Update: Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

View source ↗

Summary

Clinical trial update on MaaT013 for an Early Access Program in steroid-refractory acute graft-versus-host disease of the intestine. The sponsor is MaaT Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• MaaT013

Snippet

Sponsor: MaaT Pharma | Conditions: Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD | Status: AVAILABLE